Tratamiento quimioterápico tópico de la queratosis actínica y el cáncer cutáneo no melanoma: situación actual y perspectivas

Barrera, Maria Victoria; Herrera, E.

doi:10.1016/s0001-7310(07)70133-3

Cited by 19 publications

(3 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…5-FU has been considered the topical treatment of choice for actinic keratosis since its approval in 1970 by the US FDA [3] and it is indicated for the treatment of basal cell carcinoma [4]. For SCC treatment, although potentially promising results have been shown [5], the relative long treatment period and partial inefficacy in the deep layers of skin limit its uses.…”

Section: Introductionmentioning

confidence: 99%

Cetuximab Immunoliposomes Enhance Delivery of 5-FU to Skin Squamous Carcinoma Cells

Petrilli¹,

Eloy²,

Lopez³

et al. 2017

ACAMC

View full text Add to dashboard Cite

Topical chemotherapy of skin cancers is a promising strategy for reduction of side effects and for improvement of patient compliance. The combination of the chemotherapeutic 5-fluouracil (5-FU) and the anti-EGFR antibody cetuximab is a strategy to inhibit tumor growth. Their skin penetration, however, is hampered by their high hydrophilicity, which could be improved by encapsulation in delivery systems. Furthermore, it is a challenge to encapsulate hydrophilic drugs. The conjugation of an antibody to a liposome, maintaining its activity, is also a difficult task. Thus, we aimed to develop 5-FU liposomes and cetuximab-conjugated liposomes (immunoliposomes) of 5-FU to improve drug cytotoxicity against skin cancer cells. We characterized them by particle size, zeta potential, loading efficiency and antibody integrity. To optimize the loading efficiency of 5-FU, a series of liposomes were prepared, using different methods and drug-to-lipid ratios. Liposomes containing DSPC and Chol at drug-to-lipid ratio 0.1 prepared by the thin lipid hydration method resulted in the best 5-FU encapsulation and were chosen to conjugate with cetuximab. Cetuximab was directly coupled to preformed liposomes using DSPE-mPEG2000-Mal as an anchor. In A431 skin carcinoma cells, at 72 h, 5-FU liposomes showed a 5-fold lower IC50 than 5-FU solution. Additionally, 5-FU immunoliposomes resulted in a 4-fold lower cetuximab IC50 than cetuximab solution, demonstrating synergism with a combination index lower than 1 and potential to improve 5-FU and cetuximab cytotoxicity.

show abstract

Section: Introductionmentioning

confidence: 99%

Cetuximab Immunoliposomes Enhance Delivery of 5-FU to Skin Squamous Carcinoma Cells

Petrilli¹,

Eloy²,

Lopez³

et al. 2017

ACAMC

View full text Add to dashboard Cite

show abstract

“…Current topical treatments for skin cancer include semisolid formulations of 5-fluorouracil [73], diclofenac [73], and imiquimod. Another topical treatment also used and approved by the US Food and Drug Administration (FDA) is photodynamic therapy (PDT) [74].…”

Section: Transdermal Drug Delivery Nanoparticles In Skin Cancersmentioning

confidence: 99%

Drug Delivery Nanoparticles in Skin Cancers

Dianzani

Zara

Maina

et al. 2014

BioMed Research International

140

111

View full text Add to dashboard Cite

Nanotechnology involves the engineering of functional systems at nanoscale, thus being attractive for disciplines ranging from materials science to biomedicine. One of the most active research areas of the nanotechnology is nanomedicine, which applies nanotechnology to highly specific medical interventions for prevention, diagnosis, and treatment of diseases, including cancer disease. Over the past two decades, the rapid developments in nanotechnology have allowed the incorporation of multiple therapeutic, sensing, and targeting agents into nanoparticles, for detection, prevention, and treatment of cancer diseases. Nanoparticles offer many advantages as drug carrier systems since they can improve the solubility of poorly water-soluble drugs, modify pharmacokinetics, increase drug half-life by reducing immunogenicity, improve bioavailability, and diminish drug metabolism. They can also enable a tunable release of therapeutic compounds and the simultaneous delivery of two or more drugs for combination therapy. In this review, we discuss the recent advances in the use of different types of nanoparticles for systemic and topical drug delivery in the treatment of skin cancer. In particular, the progress in the treatment with nanocarriers of basal cell carcinoma, squamous cell carcinoma, and melanoma has been reported.

show abstract

“…It has therefore been investigated as means for delivering various anti‐proliferative agents . Topical drugs including retinoids, 5‐fluoracil, and diclofenac have been used in the therapeutic management of skin cancers or their precursor lesions . Occurring multiply on the exposed parts of the body such as the head, face, neck, and back, skin cancers usually do not require systemic drug exposure, which either requires a dose limitation or causes serious side effects .…”

Section: Introductionmentioning

confidence: 99%

Epirubicin-Loaded Superparamagnetic Iron-Oxide Nanoparticles for Transdermal Delivery: Cancer Therapy by Circumventing the Skin Barrier

Rao

Chen

Liang

et al. 2014

Small

View full text Add to dashboard Cite

The transdermal administration of chemotherapeutic agents is a persistent challenge for tumor treatments. A model anticancer agent, epirubicin (EPI), is attached to functionalized superparamagnetic iron-oxide nanoparticles (SPION). The covalent modification of the SPION results in EPI-SPION, a potential drug delivery vector that uses magnetism for the targeted transdermal chemotherapy of skin tumors. The spherical EPI-SPION composite exhibits excellent magnetic responsiveness with a saturation magnetization intensity of 77.8 emu g(-1) . They feature specific pH-sensitive drug release, targeting the acidic microenvironment typical in common tumor tissues or endosomes/lysosomes. Cellular uptake studies using human keratinocyte HaCaT cells and melanoma WM266 cells demonstrate that SPION have good biocompatibility. After conjugation with EPI, the nanoparticles can inhibit WM266 cell proliferation; its inhibitory effect on tumor proliferation is determined to be dose-dependent. In vitro transdermal studies demonstrate that the EPI-SPION composites can penetrate deep inside the skin driven by an external magnetic field. The magnetic-field-assisted SPION transdermal vector can circumvent the stratum corneum via follicular pathways. The study indicates the potential of a SPION-based vector for feasible transdermal therapy of skin cancer.

show abstract

Tratamiento quimioterápico tópico de la queratosis actínica y el cáncer cutáneo no melanoma: situación actual y perspectivas

Cited by 19 publications

References 23 publications

Cetuximab Immunoliposomes Enhance Delivery of 5-FU to Skin Squamous Carcinoma Cells

Cetuximab Immunoliposomes Enhance Delivery of 5-FU to Skin Squamous Carcinoma Cells

Drug Delivery Nanoparticles in Skin Cancers

Epirubicin-Loaded Superparamagnetic Iron-Oxide Nanoparticles for Transdermal Delivery: Cancer Therapy by Circumventing the Skin Barrier

Contact Info

Product

Resources

About